Is $99 Semaglutide Real? Why Compounded GLP-1 Costs 90% Less Than Brand-Name
How is $99/month semaglutide possible when Wegovy costs $1,300? This guide explains the economics, legality, and quality standards behind compounded semaglutide — and what to look for in a safe provider.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes only.
More on Education
When people first see "$99/month semaglutide," the most common reaction is skepticism — and that skepticism is healthy. Brand-name Wegovy costs $1,300–$1,500 per month. How can the same molecule be available for under $100?
The short answer: compounded semaglutide is legal, real, and available at a fraction of the brand-name price because it bypasses the patent-protected commercial supply chain. The long answer involves understanding pharmaceutical compounding law, the economics of drug pricing, and what quality safeguards you should verify before starting.
This article explains all of it clearly — no promotional language, no hand-waving. If you are evaluating whether $99/month semaglutide is legitimate, this is the guide to read.
Why Wegovy Costs $1,300 — And Why That Price Is Unusual
To understand why compounded semaglutide can cost $99/month, you first need to understand why brand-name Wegovy costs $1,300. The answer is not "because the molecule is expensive to make." The answer is patent exclusivity and market structure.
The components of brand-name drug pricing
- R&D cost recovery: Novo Nordisk spent over a decade and billions of dollars developing semaglutide through clinical trials, regulatory submissions, and manufacturing scale-up. That investment needs to be recouped through drug sales.
- Patent exclusivity: Semaglutide patents prevent any other company from producing a generic equivalent. Without competition, Novo Nordisk has broad pricing power. This is the single largest driver of the price gap.
- Commercial manufacturing and distribution: Large-scale manufacturing, cold-chain shipping, auto-injector device development, and global distribution networks add meaningful cost.
- Marketing and physician outreach: Novo Nordisk spends hundreds of millions annually on direct-to-consumer advertising and physician marketing for Ozempic and Wegovy.
- PBM and insurer negotiations: Pharmacy benefit managers negotiate rebates that may reduce what insurers pay — but these rebates are not typically reflected in the retail or cash price.
Compounding pharmacies carry none of these costs except the cost of API, preparation, quality testing, and dispensing. That is why the same molecule can be produced and dispensed for $99/month.
What Is Pharmaceutical Compounding?
Pharmaceutical compounding is the preparation of a customized medication from individual ingredients by a licensed pharmacy or pharmacist. It exists under a dedicated legal framework — Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act — that allows compounding pharmacies to prepare medications not commercially available, in alternative dosage forms, or from components that meet FDA quality standards.
503A vs. 503B: Two types of compounding pharmacies
503A — Traditional Compounding Pharmacies
These are licensed state pharmacies that compound on a per-patient, prescription-by-prescription basis. They are regulated by state pharmacy boards and must follow USP standards for compounding. Quality depends heavily on the individual pharmacy. For injectable medications like semaglutide, patients should verify whether a 503A pharmacy has specific sterile compounding accreditation (PCAB).
503B — Outsourcing Facilities (Higher Standard)
These facilities are registered with the FDA and subject to cGMP (Current Good Manufacturing Practice) standards similar to commercial drug manufacturers. They can produce larger batches for distribution across states. FDA inspects 503B facilities regularly. For injectable medications, 503B outsourcing facilities represent the highest standard of quality assurance in the compounding sector. Trimi partners with 503B and PCAB-accredited pharmacies.
The Anatomy of a $99/Month Compounded Semaglutide Program
Here is exactly what makes the Trimi $99/month program work economically and operationally.
| Component | Brand-name (Wegovy) | Compounded (Trimi) |
|---|---|---|
| Active ingredient | Semaglutide (Novo Nordisk) | Semaglutide API (pharmaceutical-grade) |
| Dose schedule | Weekly injection, 0.25mg→2.4mg over 16–20 weeks | Same dose titration protocol |
| Manufacturer | Novo Nordisk (commercial facility) | FDA-registered 503B / PCAB-accredited pharmacy |
| Delivery device | Novo Nordisk FlexTouch auto-injector | Multi-dose vial with syringes |
| Quality testing | Commercial cGMP standards | Third-party potency, sterility, endotoxin testing |
| Monthly price | $1,300–$1,500 | $99 |
| Insurance required | Preferred (PA required) | No — cash-pay direct |
Is It Actually the Same Drug? The Molecular Reality
Semaglutide is a specific molecule: a glucagon-like peptide-1 (GLP-1) receptor agonist with a defined molecular structure and a fatty acid chain that extends its half-life to approximately seven days. This is the same molecular identity whether it is in Wegovy, Ozempic, or a compounded preparation.
The pharmaceutical-grade semaglutide API used by quality compounding pharmacies is tested to confirm molecular identity, purity, and potency before dispensing. The patient's body cannot distinguish between semaglutide from Novo Nordisk's pen injector and semaglutide from an accredited compounding pharmacy vial — because the molecule is the same.
What does differ:
- Delivery device: compounded uses vial + syringe vs. Wegovy's auto-injector pen
- Inactive excipients: the stabilizers, preservatives, and diluents may differ (not clinically significant for most patients)
- Manufacturing oversight: 503B outsourcing facilities are subject to FDA cGMP inspection; 503A pharmacies to state board oversight
- Labeling and packaging: brand-name has FDA-approved labeling; compounded does not carry FDA-approved labeling
For a full evidence review of clinical outcomes with compounded vs. brand-name semaglutide, see does compounded semaglutide work as well as Ozempic?
Quality Safeguards: What Separates Legitimate from Risky
Not all $99 semaglutide offers are equal. The quality of the medication depends entirely on the pharmacy's practices. Here is exactly what to verify before starting a compounded semaglutide program.
Non-negotiable quality markers
- Provider-issued prescription required: No legitimate compounding program dispenses semaglutide without a prescription from a licensed healthcare provider who has reviewed your health history.
- Named, verifiable pharmacy: The pharmacy's name, state license, and FDA registration (for 503B facilities) should be disclosed and verifiable through NABP's online lookup or the FDA's 503B database.
- Certificate of Analysis (COA) available: Third-party lab certificates confirming potency (within ±10% of labeled dose), sterility, and endotoxin levels should be available for each batch.
- PCAB accreditation or 503B FDA registration: PCAB (Pharmacy Compounding Accreditation Board) accreditation is the gold standard for 503A pharmacies. FDA 503B registration is required for outsourcing facilities.
- Ongoing provider relationship: A legitimate program includes access to a licensed provider for dose adjustments, side-effect management, and clinical questions — not just a one-time evaluation.
Red flags to avoid
- No prescription required — this is a federal law violation
- Price under $40–$50/month — below the cost of pharmaceutical-grade API and testing
- Pharmacy name not disclosed or not verifiable through NABP/FDA databases
- No third-party testing documentation available on request
- Claims of FDA approval for the compounded product itself (compounded drugs are not FDA-approved)
- Ships from outside the United States
The FDA's Position on Compounded Semaglutide
The FDA's regulatory stance on compounded semaglutide has evolved with the drug shortage situation. During periods when semaglutide was on the FDA drug shortage list (2022–2024), 503B outsourcing facilities and 503A pharmacies were explicitly permitted to compound semaglutide under shortage-related provisions.
As of 2026, compounded semaglutide availability continues to be governed by FDA guidance on compound pharmacies generally (Sections 503A and 503B of the FD&C Act) as well as any current shortage status updates. The FDA has issued guidance documents about compounded GLP-1 medications that patients and providers should review for current status.
Trimi monitors FDA guidance in real-time and works with legal and regulatory counsel to ensure its programs comply with current federal law. We recommend patients always verify the current regulatory status directly through the FDA website.
Frequently Heard Skepticisms — Answered Honestly
"If it's so good, why isn't everyone doing it?"
Awareness is the primary barrier. Most patients learn about GLP-1 medications from their doctor, who prescribes brand-name drugs. Compounded options are not advertised by Novo Nordisk. Telehealth providers like Trimi have grown rapidly because they fill this information gap — but the majority of people seeking semaglutide still do not know compounded options exist.
"Too good to be true usually means it is."
A healthy heuristic — but not universally applicable. The price difference exists because of a specific structural reason (patent exclusivity) that compounding legally bypasses. Chemotherapy drugs prepared by compounding pharmacies, custom hormone formulations, and specialized injectable nutrients have operated on this model for decades. The molecule's legitimate $99 price is explained by the economics, not by a quality shortcut.
"My doctor said not to use compounded semaglutide."
Some physicians are skeptical of compounded medications generally or have concerns about specific unaccredited providers. These concerns have merit for low-quality compounders. The appropriate response is to ask your doctor specifically what concerns they have and whether those concerns apply to 503B-registered pharmacies with third-party batch testing. If their objection is to a specific low-quality source, that is reasonable. If it is to compounded semaglutide categorically, the evidence does not support that blanket position.
"Won't it be banned soon?"
FDA has issued guidance on compounded GLP-1 medications and has updated its position as semaglutide shortage status changes. Trimi monitors regulatory developments continuously. Patients who start a program should stay informed about any changes through their provider.
How to Get Started with Trimi's $99/Month Program
Trimi's program is designed to be the fastest and most transparent pathway to compounded semaglutide. Here is exactly how it works:
- 1Complete an online health assessment covering your medical history, current medications, weight history, and goals
- 2A board-certified provider reviews your submission — typically within 24 hours — and evaluates clinical eligibility for semaglutide
- 3If appropriate, your prescription is sent to an FDA-registered 503B or PCAB-accredited 503A compounding pharmacy
- 4Medication is prepared, batch-tested, and shipped within 2–3 business days
- 5You receive semaglutide with a multi-dose vial, syringes, dose-titration schedule, and provider contact information
- 6Monthly refills at $99/month with ongoing provider access for adjustments
Questions about the clinical side? See does compounded semaglutide produce the same weight-loss results as Ozempic? and how online GLP-1 prescriptions work in 2026.
Frequently Asked Questions
Is $99/month semaglutide legitimate?
Yes — when provided by a licensed telehealth company through FDA-registered compounding pharmacies with a valid prescription. Compounded semaglutide is legal under U.S. federal compounding law (Sections 503A and 503B of the FD&C Act). The $99 price is achievable because compounding pharmacies do not carry Novo Nordisk's patent premium, commercial manufacturing overhead, or marketing costs. The active ingredient is pharmaceutical-grade semaglutide API — the same molecule as Wegovy.
Why does brand-name Wegovy cost $1,300 when the molecule is the same?
Brand-name drug pricing reflects patent exclusivity, clinical development costs, commercial manufacturing scale, global distribution, marketing, and profit margins. Novo Nordisk spent over a decade and billions of dollars developing and trialing semaglutide. Patents prevent generic competition, so the only market check on price is manufacturer assistance programs and licensed compounding. Compounding pharmacies do not hold these costs — they purchase pharmaceutical-grade API and prepare the formulation at a fraction of the commercial price.
Is compounded semaglutide the same active ingredient as Wegovy?
Yes. Compounded semaglutide uses semaglutide — the same GLP-1 receptor agonist molecule — as the active pharmaceutical ingredient. The dose titration schedule, injection frequency, mechanism of appetite suppression, and expected weight-loss trajectory are identical to Wegovy. What differs is the manufacturer: Novo Nordisk versus a licensed compounding pharmacy.
What quality risks exist with compounded semaglutide?
The main risks involve pharmacy quality practices: inaccurate dosing (either too low to be effective or too high to be safe), sterility failures in injectable preparation, and contamination. These risks are minimal when the pharmacy is FDA-registered, PCAB-accredited, and conducts third-party potency, sterility, and endotoxin testing on each batch. Patients should verify pharmacy credentials before ordering. The risks are substantially higher from unverified sources that do not require a prescription.
Is it legal to buy compounded semaglutide?
Compounded semaglutide prepared by a licensed 503B outsourcing facility or 503A compounding pharmacy pursuant to a valid prescription from a licensed provider is legal under federal law. Patients receive it through a telehealth provider relationship, not direct-to-consumer without a prescription. It is not legal to import foreign semaglutide or purchase semaglutide 'for research purposes' without a prescription for personal use.
How do I know if a $99 semaglutide offer is legitimate versus a scam?
Legitimate providers: require a medical evaluation before prescribing, use named accredited compounding pharmacies, provide certificate of analysis (COA) for batch testing, have licensed providers you can contact, and disclose full pricing with no hidden fees. Red flags: no prescription required, pharmacy name not disclosed, no quality documentation, price 'too good to be true' (under $50/month), and no medical evaluation. Trimi meets all legitimacy criteria.
What happens to the price of compounded semaglutide when brand-name patents expire?
When Novo Nordisk's semaglutide patents expire (expected mid-to-late 2030s depending on jurisdiction), FDA-approved generic semaglutide manufacturers will enter the market. Generic competition historically reduces prices by 70–90%. At that point, FDA-approved generic semaglutide may be priced comparably to compounded versions. Until then, compounding pharmacies remain the primary affordable alternative.
Related Reading
Sources & References
- FDA. Compounding and the FDA: Questions and Answers.
- FDA. 503B Outsourcing Facilities — overview and database.
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide. NEJM 2021;384:989–1002.
- NABP. Pharmacy Compounding Accreditation Board (PCAB).
- FDA Drug Shortage Database — current shortage status.
- FDA prescribing information for Wegovy (semaglutide injection 2.4mg).
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication. Trimi provides compounded semaglutide through licensed providers and accredited pharmacies — this article reflects our perspective and should be read alongside current FDA guidance on compounded GLP-1 medications.